Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats

Bitget App

Trade smarter

Bitget

News

Markets

Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats

Bitget-RWA2025/11/23 20:30

By:Bitget-RWA

- Novartis raised 2030 sales growth targets to 5-6% annually, driven by high peak sales expectations for oncology drugs Kisqali and Scemblix. - CEO Vas Narasimhan highlighted eight de-risked drugs with $3-10B peak potential, but analysts warned of patent expirations and uncertain pipeline progress beyond 2030. - Shares rose 0.5% post-announcement, while Exact Sciences surged 17% on its $105/share acquisition by Abbott and Samsung Biologics saw a 71% valuation re-rating after spin-off. - J.P. Morgan caution

Swiss pharmaceutical leader

Novartis AG

(NOVN.SW) has updated its medium-term revenue outlook,

projecting annual sales growth of 5% to 6% in constant currency through 2030

, fueled by higher anticipated peak sales for its flagship oncology treatments Kisqali and Scemblix. This revised forecast,

shared at a management meeting in London

, signals the company’s optimism in its product lineup even as major drugs like Cosentyx and Entresto approach patent expiration. CEO Vas Narasimhan highlighted the robustness of Novartis’s development pipeline, which features eight lower-risk drugs each with peak sales potential between $3 billion and $10 billion, along with more than 30 promising candidates in advanced development.

Experts remain split on whether Novartis can maintain this growth trajectory. While

Stefan Schneider of Vontobel commended

the company for reliably meeting its goals and raising its peak sales forecasts for Kisqali (now $10 billion) and Scemblix ($4 billion), J.P. Morgan pointed to challenges from patent cliffs and uncertainties in the drug pipeline after 2030. The bank

observed that reaching $72.4 billion in sales by 2030

will depend on strong clinical trial outcomes and regulatory green lights. Following the news, shares of

Novartis

gained 0.5%,

bringing the stock’s year-to-date increase to 16%

Pre-market trading in the pharmaceutical industry was mixed.

Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats image 0

Exact Sciences jumped more than 17%

after Abbott Laboratories announced plans to buy the liquid biopsy company for $105 per share. At the same time, Super Micro Computer (SMCI) rose over 5% after unveiling new GPU systems that use AMD’s Instinct MI355X chips.

Samsung Biologics, a contract development and manufacturing organization (CDMO) based in South Korea, is set for further expansion after spinning off its biosimilar business.

Analyst Yisoo Jeong from IBK Securities believes

that this move could help attract additional CDMO deals by easing clients’ worries about their intellectual property being exposed to Samsung’s own drug development. According to the analyst, the change

has led to a 71% upward revision

in the company’s valuation.

Novartis’s new outlook also highlighted the significance of its upcoming milestones. The company anticipates more than 15 pivotal readouts over the next two years,

including results from advanced-stage cancer and rare disease studies

. Still,

J.P. Morgan warned that pricing challenges

for Kisqali in the U.S. could become an obstacle, especially if the drug is subject to Medicare price negotiations.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

- JPMorgan's closure of Strike CEO Jack Mallers' accounts contradicts Trump's August executive order banning crypto "debanking," sparking regulatory scrutiny. - Mallers criticized the lack of transparency, noting JPMorgan cited "concerning activity" without specifics and warned against future account access. - Industry experts argue such actions risk pushing crypto innovation to unregulated markets, undermining U.S. financial leadership and democratic systems. - The incident highlights contradictions in JP

Bitget-RWA•2025/11/24 09:24

Bitcoin News Update: With Trump's Crypto Faltering, Investors Turn to Stablecoins for Security

- Trump's crypto investments lost $1B as ABTC and TMTG collapsed, prompting a shift to stablecoins exceeding $300B market cap. - Trump Media's $250M Bitcoin investment initially boosted shares but was overshadowed by broader crypto market declines. - SEC probes and central bank warnings highlight risks in politically connected crypto projects and stablecoin redemption vulnerabilities. - Despite losses, Trump family members remain bullish on Bitcoin, while DOGE meme coin surged post-program termination. - M

Bitget-RWA•2025/11/24 09:24

Bitcoin News Update: With Trump's Crypto Faltering, Investors Turn to Stablecoins for Security

Investors Abandon HBAR Due to Instability, Turn to Small-Cap Options

- HBAR price collapsed below $0.1440, triggering bearish signals as key support levels failed to hold amid surging trading volume. - Zero-volume trading halts and distribution patterns highlight liquidity risks, with critics questioning market depth infrastructure. - Investors shift toward low-cap alternatives as HBAR's volatility contrasts with gains in fintech (SoFi +87.7%) and space-tech (BlackSky $71.4M revenue). - Analysts warn further downside to $0.1340 remains likely without institutional support,

Bitget-RWA•2025/11/24 09:24

Investors Abandon HBAR Due to Instability, Turn to Small-Cap Options

ECB Cautions That Fluctuations in Tech and Crypto May Trigger a Market Crash Similar to 2000

- ECB warns U.S. tech and crypto volatility risks triggering a 2000-style market crash, citing sharp asset corrections and AI-driven valuation fragility. - ECB officials stress central banks must retain rate-cut flexibility amid rising risks, as crypto outflows and equity inflows highlight market divergence. - JPMorgan analysis flags crypto panic-selling risks spilling into broader systems, while MSCI warns a 63% sector collapse could follow AI confidence loss. - ECB and BIS caution stablecoin growth threa

Bitget-RWA•2025/11/24 09:06